1. Pink Sheet
  2. >>Market Access

Louisiana Subscription Contract For Generic Epclusa About Access, Not Discounts

 
• By Cathy Kelly

Innovative purchasing model is not designed to solve the problem of high drug costs, experts point out during a recent discussion at the Brookings Institution.

Subscription vs One-Time Payment - Traffic sign with two options - subscribe periodical service and product vs singular purchase and payment. - Image
Subscription Model Might Also Work For Sickle Cell, Hemophilia Treatments

 The state of Louisiana’s innovative subscription purchasing model for the authorized generic version of Gilead Sciences Inc.’s hepatitis C drug Epclusa is primarily designed to ensure patient access to the treatment and not necessarily to lower state spending on the drug.

“The pitch was always this: it was never about just a slightly better price or a better deal,” Louisiana Department...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

New EU Filings

 
• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.